LLY

1,123.54

+3.6%↑

JNJ

231.47

+0.05%↑

ABBV

218.3

+1.32%↑

UNH

383.9

+0.44%↑

MRK

120.03

-0.68%↓

LLY

1,123.54

+3.6%↑

JNJ

231.47

+0.05%↑

ABBV

218.3

+1.32%↑

UNH

383.9

+0.44%↑

MRK

120.03

-0.68%↓

LLY

1,123.54

+3.6%↑

JNJ

231.47

+0.05%↑

ABBV

218.3

+1.32%↑

UNH

383.9

+0.44%↑

MRK

120.03

-0.68%↓

LLY

1,123.54

+3.6%↑

JNJ

231.47

+0.05%↑

ABBV

218.3

+1.32%↑

UNH

383.9

+0.44%↑

MRK

120.03

-0.68%↓

LLY

1,123.54

+3.6%↑

JNJ

231.47

+0.05%↑

ABBV

218.3

+1.32%↑

UNH

383.9

+0.44%↑

MRK

120.03

-0.68%↓

Kodu・Aktsiate loetelu・Vaxart Inc

Vaxart Inc

Avatud

0.34

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.34

Max

0.34

Põhinäitajad
By Trading Economics
Sissetulek	-50M 5.2M
Müük	-65M 39M
P/E Sektori keskmine	4 50.102
Aktsiakasum	0.02
Kasumimarginaal	13.203
Töötajad	65
EBITDA	-51M 6.8M

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-29M 154M
Eelmine avamishind	0.34
Eelmine sulgemishind	0.34

Vaxart Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. mai 2026, 21:33 UTC

Tulu

Correction to Salesforce 1Q Sales, Profit Rise Article

27. mai 2026, 21:00 UTC

Omandamised, ülevõtmised, äriostud

HCA Healthcare Agrees to Buy The College of Health Care Professions

27. mai 2026, 20:18 UTC

Tulu

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

27. mai 2026, 23:49 UTC

Market Talk

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

27. mai 2026, 23:39 UTC

Market Talk

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

27. mai 2026, 23:34 UTC

Market Talk

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

27. mai 2026, 23:34 UTC

Market Talk

Global Equities Roundup: Market Talk

27. mai 2026, 23:08 UTC

Market Talk

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

27. mai 2026, 22:21 UTC

Market Talk

Salesforce Lays Out AI Monetization Strategy -- Market Talk

27. mai 2026, 21:29 UTC

Kuumad aktsiad

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

27. mai 2026, 21:08 UTC

Tulu

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

27. mai 2026, 21:02 UTC

Tulu

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

27. mai 2026, 20:59 UTC

Omandamised, ülevõtmised, äriostud

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

27. mai 2026, 20:55 UTC

Tulu

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

27. mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

27. mai 2026, 20:48 UTC

Tulu

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

27. mai 2026, 20:45 UTC

Tulu

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

27. mai 2026, 20:34 UTC

Omandamised, ülevõtmised, äriostud

Webster Financial Stockholders Approve Sale to Banco Santander

27. mai 2026, 20:32 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

27. mai 2026, 20:32 UTC

Omandamised, ülevõtmised, äriostud

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

27. mai 2026, 20:32 UTC

Omandamised, ülevõtmised, äriostud

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

27. mai 2026, 20:30 UTC

Tulu

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

27. mai 2026, 20:30 UTC

Omandamised, ülevõtmised, äriostud

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

27. mai 2026, 20:22 UTC

Tulu

Salesforce Stock Slides on Mixed Results -- Barrons.com

27. mai 2026, 20:16 UTC

Tulu

Salesforce Stock Slides on Mixed Results -- Barrons.com

27. mai 2026, 20:13 UTC

Tulu

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

27. mai 2026, 20:13 UTC

Tulu

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

27. mai 2026, 20:13 UTC

Tulu

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

27. mai 2026, 20:12 UTC

Tulu

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

27. mai 2026, 20:12 UTC

Tulu

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Võrdlus sarnastega

Hinnamuutus

Vaxart Inc Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

Osta

Hoia

Müü

Põhineb 0 analüütiku instrumendi Vaxart Inc aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.